Fakhrul Hassan

Dr. Fakhrul Hassan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 February 2026 in Current Research in Structural Biology
Verified
Journal Article
Open access
AKAbbas Khan
Abbas Khan
MSMona A. Sawali
Mona A. Sawali
MSMohanad Shkoor
Mohanad Shkoor
FHFakhrul Hassan
Fakhrul Hassan
ASAlrayyan Private school
Alrayyan Private school
AAAbdelali Agouni
Abdelali Agouni
Bruton tyrosine kinase (BTK) is a non-receptor tyrosine kinase crucial for relaying signals from the B cell antigen receptor (BCR) in cancerous B lymphocytes. It has been reported that mutations in this protein cause resistance to various covalent and non-covalent drugs. Therefore, we employed a computational genomic mutation screening strategy, combined with molecular simulation, to assess the impact of clinical substitutions on the structure and binding of ARQ 531(Nemtabrutinib), the most potent BTK inhibitor. Using various machine learning algorithms, 62 clinical mutations were identified as deleterious among the 82, while 11 were classified as highly destabilizing using graph signature-based methods. We selected the top mutations that are deleterious and highly destabilizing, which include L408P, Y476D, M477R, C481R, C481Y, and L542P. Molecular docking analysis revealed no significant variations in the bonding network, while molecular simulation results revealed local changes only in the dynamic behavior. The resemblance to the wild type and mutants in certain PCs (principal components) implies that specific structural aspects or dynamics remain preserved despite the mutation, and the single energetic minimum indicates a robust and dominant structural state, reinforcing that these mutations affect the protein locally but not globally. Finally, the total binding free energy (TBE) calculations revealed that ARQ531 exhibits broadly conserved binding energetics across clinically observed BTK mutants, with select variants (notably C481 substitutions) showing moderately enhanced stabilization relative to the wild type. These findings confirm that ARQ 531 remains a significant investigational therapy specifically for overcoming drug resistance in multiple leukemias and B-cell malignancies and can serve as a starting point for designing more robust and effective BTK inhibitors.

19 January 2026 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
FHFakhrul Hassan
Fakhrul Hassan
AKAbbas Khan
Abbas Khan
MSMuhammad Suleman
Muhammad Suleman
Faez Iqbal KhanFaez Iqbal Khan
Faez Iqbal Khan
IGIjaz Gul
Ijaz Gul